(Press-News.org) Age and testing of hip bone mineral density (BDM) when postmenopausal women discontinue bisphosphonate therapy can help predict the likelihood of fractures over the next five years.
Bisphosphonates can reduce the risk of hip and spine fractures. But recent concerns about safety issues, including osteonecrosis of the jaw, atypical femoral fractures and esophageal cancer, have increased interest in interrupting or stopping bisphosphonate therapy after several years of treatment. This study tested methods for predicting fracture risk by measuring BMD using hip and spine duel-energy x-ray absorptiometry (DXA) and also bone turnover markers (BTMs) when women discontinue bisphosphonate therapy and a few years afterward.
The Fracture Intervention Trial Long-term Extension (FLEX) randomly assigned postmenopausal women (ages 61 to 86 years) previously treated with the bisphosphonate alendronate sodium (for four to five years) to five additional years of alendronate or placebo from 1998 through 2003. This analysis included only the placebo group. Hip and spine DXA were measured when the placebo was started and after one to three years of follow-up. Two different BTMs also were measured at baseline and after one and three years.
During five years of placebo, 22 percent of women (94 of 437) had one or more fractures; 82 had fractures after one year. Older age and lower hip BMD at the time alendronate therapy was discontinued were associated with higher rates of clinical fractures during the subsequent five years. However, neither BMD measures after one-year nor BTM levels one- to two -years after discontinuing alendronate were associated with fracture risk.
"Women with greater total hip bone loss two or three years after discontinuation may be at increased risk of fracture, but these results need to be confirmed in other studies before routine measurement of BMD after discontinuation of alendronate therapy can be recommended. … In the meantime, short-term monitoring with BMD, BAP or NTX [two bone turnover markers] after discontinuation of four to five years of alendronate therapy does not appear to improve fracture prediction."
INFORMATION:
Author: Douglas C. Bauer, M.D., of the University of California, San Francisco, and colleagues.
(JAMA Intern Med. Published online May 5, 2014. doi:10.1001/jamainternmed.2014.1232. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: The FLEX study was supported by contracts from Merck & Co.; this analysis was designed and conducted by the non-Merck investigators without additional financial support. The authors made conflict of interest disclosures. The study drug was manufactured and packaged by Merck. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Commentary: Monitoring After Discontinuation of Bisphosphonate Therapy
In a related commentary, Margaret L. Gourlay, M.D., M.P.H., of the University of North Carolina-Chapel Hill, and Kristine E. Ensrud, M.D., M.P.H., of the University of Minnesota Medical School, Minneapolis, write: "In this issue of JAMA Internal Medicine, Bauer and colleagues provide clinically useful data from the placebo group of the Fracture Intervention Trial Long-term Extension (FLEX) trial regarding the value of BMD and bone turnover marker measurements after completion of a five-year course of alendronate therapy."
"The study of Bauer and colleagues is convincing because of its reliance on a clinical (symptomatic) fracture outcome rather than surrogate measures such as rates of BMD loss or changes in bone turnover marker levels. The study also raises new questions about appropriate clinical use and testing of bisphosphonates," they continue.
"In an era when we know much more about how to start alendronate therapy than how to stop it, the results of Bauer and colleagues suggest that identification of patients at high risk of fracture after treatment discontinuation is best accomplished by BMD measurement at the time of discontinuation rather than frequent short-term monitoring with BMD or bone turnover marker measurements after treatment discontinuation," they conclude.
(JAMA Intern Med. Published online May 5, 2014. doi:10.1001/jamainternmed.2014.162. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: An author made a conflict of interest disclosure. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Media Advisory: To contact author Douglas C. Bauer, M.D., call Elizabeth Fernandez at 415-514-1592 or email Elizabeth.Fernandez@ucsf.edu. To contact commentary author Margaret L. Gourlay, M.D., call Stephanie Mahin at 919-966-2860 or email Stephanie.Mahin@unchealth.unc.edu.
Study looks at predicting fracture risk after women stop bisphosphonate therapy
2014-05-05
ELSE PRESS RELEASES FROM THIS DATE:
Choosing a screening method for cervical cancer: Pap alone or with HPV test
2014-05-05
Karen Smith-McCune, M.D., Ph.D., of the University of California, San Francisco, writes: "The updated guidelines leave physicians and other clinicians with a question: is cotesting with Pap-plus-HPV testing truly preferred over Pap testing alone (the American Cancer Society/the American Society of Colposcopy and Cervical Pathology/the American Society of Clinical Pathology recommendation), or are the options equivalent (the U.S. Preventive Services Task Force recommendation)?"
"Once a straightforward process, screening for cervical cancer is now increasingly complex. ...
Eliminating copayments improves adherence, reduces adverse events in nonwhite patients
2014-05-05
Research demonstrates that lowering copayments for cardiovascular medications results in better adherence and outcomes among all patients, but until now, little was known about whether lowering copayments could improve known disparities in cardiovascular care. New research finds that lowering copayments for medications following a heart attack could have a significant impact on reducing the racial and ethnic disparities that exist in cardiovascular disease.
These findings are published in the May issue of Health Affairs.
"African Americans and Hispanics with cardiovascular ...
Women with unintended pregnancies take the shortest maternity leaves
2014-05-05
College Park, Md. -- Mothers in the United States who have unintended pregnancies return to work sooner after childbirth than mothers whose pregnancy was intended, according to a study led by Dr. Rada K. Dagher, assistant professor of health services administration in the University of Maryland School of Public Health.
This is the first study to examine pregnancy intention and return to work after childbirth. "We know that it's better for women to take time off after childbirth to take care of their physical and mental health," says Dr. Dagher, whose previous research ...
Evolution in species may reverse predator-prey population cycles
2014-05-05
Populations of predators and their prey usually follow predictable cycles. When the number of prey increases – perhaps as their food supply becomes more abundant – predator populations also grow.
When the predator population becomes too large, however, the prey population often plummets, leaving too little food for the predators, whose population also then crashes. This canonical view of predator-prey relationships was first identified by mathematical biologists Alfred Lotka and Vito Volterra in the 1920s and 1930s.
But all bets are off if both the predator and prey ...
Monitoring RNA levels in blood yields dynamic picture of fetal development, disease
2014-05-05
STANFORD, Calif. — Recent research has shown that tiny fragments of DNA circulating in a person's blood can allow scientists to monitor cancer growth and even get a sneak peek into a developing fetus' gene sequences. But isolating and sequencing these bits of genetic material renders little insight into how that DNA is used to generate the dizzying array of cells, tissues and biological processes that define our bodies and our lives.
Now researchers at Stanford University have moved beyond relying on the static information delivered by DNA sequences in the blood. Instead, ...
UEA research identifies molecules that guide embryonic heart-forming cells
2014-05-05
Scientists at the University of East Anglia have made an important step in understanding how hearts are formed in developing embryos.
The heart is the first functioning organ to develop in humans, and correct formation is crucial for embryo survival and growth.
New research published today reveals how cells that form the heart, known as 'cardiac progenitors', are guided to move into the right place for the heart to begin to form.
It is hoped that the findings will help researchers better understand how congenital heart defects happen during the early stages of pregnancy. ...
Immune cells outsmart bacterial infection by dying, Penn Vet study shows
2014-05-05
A new study led by scientists at the University of Pennsylvania School of Veterinary Medicine has painted a clearer picture of the delicate arms race between the human immune system and a pathogen that seeks to infect and kill human cells.
The research explores the strategies by which the bacterial pathogen Yersinia, responsible for causing plague and gastrointestinal infections, tries to outsmart immune cell responses and looks at the tactics used by the immune system to fight back.
The senior author of the paper, which appears online this week in Proceedings of the ...
Getting to the root of enamel evolution
2014-05-05
DURHAM, N.C. -- Along with our big brains and upright posture, thick tooth enamel is one of the features that distinguishes our genus, Homo, from our primate relatives and forebears. A new study, published May 5 in the Journal of Human Evolution, offers insight into how evolution shaped our teeth, one gene at a time.
By comparing the human genome with those of five other primate species, a team of geneticists and evolutionary anthropologists at Duke University has identified two segments of DNA where natural selection may have acted to give modern humans their thick enamel.
Teeth ...
Where DNA's copy machine pauses, cancer could be next
2014-05-05
DURHAM, N.C. -- Each time a human cell divides, it must first make a copy of its 46 chromosomes to serve as an instruction manual for the new cell. Normally, this process goes off without a hitch. But from time to time, the information isn't copied and collated properly, leaving gaps or breaks that the cell has to carefully combine back together.
Researchers have long recognized that some regions of the chromosome,called "fragile sites," are more prone to breakage and can be a breeding ground for human cancers. But they have struggled to understand why these weak spots ...
NeuroStar TMS Therapy shows promise as maintenance therapy for major depression
2014-05-05
NEW YORK, May 5, 2014 – Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy® for Major Depressive Disorder (MDD). Six weeks of acute NeuroStar TMS Therapy induced remission in 61.2 percent of all enrolled patients. At three months, 62.5 percent of medication-free patients randomized to once-monthly treatment with NeuroStar TMS Therapy maintained response as compared to 43.8 percent ...